Qube Research & Technologies (QRT)
ADAP

Qube Research & Technologies (QRT)’s Adaptimmune Therapeutics ADAP Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,113
Closed -$1.99K – 3512
2025
Q1 		$1.99K Buy
+10,113
New +$5.24K ﹤0.01% 3403
2024
Q1 		– Sell
-2,087
Closed -$1.66K – 4410
2023
Q4 		$1.66K Sell
2,087
-19,474
-90% -$11K ﹤0.01% 3831
2023
Q3 		$16.8K Sell
21,561
-78,589
-78% -$66K ﹤0.01% 3196
2023
Q2 		$92.6K Buy
100,150
+52,326
+109% +$62.4K ﹤0.01% 1965
2023
Q1 		$52.1K Buy
47,824
+20,823
+77% +$32.3K ﹤0.01% 2222
2022
Q4 		$39.4K Buy
+27,001
New +$43.7K ﹤0.01% 2166
2022
Q3 		– Sell
-43,966
Closed -$75K – 2462
2022
Q2 		$75K Buy
+43,966
New +$75.5K ﹤0.01% 2032
2020
Q2 		– Sell
-12,167
Closed -$33K – 1685
2020
Q1 		$33K Buy
+12,167
New +$40.4K ﹤0.01% 1032

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ADAP Position: Q2 2025 in Review

Qube Research & Technologies (QRT) sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 10,113 shares — an estimated $1.99K sold.

Qube Research & Technologies (QRT) first reported a position in ADAP in Q1 2020 and held it in 8 quarters. The position peaked at $92.6K in Q2 2023. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • Qube Research & Technologies (QRT) reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 10,113 Adaptimmune Therapeutics shares in Q2 2025, an estimated $1.99K.
  • Qube Research & Technologies (QRT) first reported a position in Adaptimmune Therapeutics in Q1 2020 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s Adaptimmune Therapeutics position peaked at $92.6K in Q2 2023.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2025, filed 14 Aug 2025.